Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

Roger J.M. Brüggemann, Jan Willem C. Alffenaar, Nicole M.A. Blijlevens, Eliane M. Billaud, Jos G.W. Kosterink, Paul E. Verweij, David M. Burger

Research output: Contribution to journalReview articlepeer-review

362 Citations (Scopus)

Abstract

There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posa- conazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.

Original languageEnglish
Pages (from-to)1441-1458
Number of pages18
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume48
Issue number10
DOIs
Publication statusPublished - 15 May 2009
Externally publishedYes

Fingerprint

Dive into the research topics of 'Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents'. Together they form a unique fingerprint.

Cite this